Global Information
회사소개 | 문의 | 비교리스트

통풍 치료제 시장 : 분석, 점유율, 규모, 동향, 예측(2020-2026년)

Gout Therapeutics Market, By Disease Condition, By Drug Class, and By Geography - Analysis, Share, Size, Trends, & Segment Forecast from 2020-2026

리서치사 AnalystView Market Insights
발행일 2020년 05월 상품 코드 937192
페이지 정보 영문 206 Pages
가격
US $ 3,250 ₩ 3,707,000 PDF (Single User Licence) help
1명만 이용할 수 있는 라이선스로 인쇄가 불가능합니다.
US $ 4,650 ₩ 5,305,000 PDF (5 User Licence) help
동일 사업장 내 5명까지 이용할 수 있는 라이선스입니다. 인쇄 횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 5,650 ₩ 6,446,000 PDF (Enterprise User Licence) help
동일 기업 내 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수 및 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.

주의 : 라이선스에 따라 자료 이용 및 인쇄 등에 제약이 있을 수 있습니다.
자세한 내용은 라이선스 설명문( )을 참고하여 주시기 바랍니다.



통풍 치료제 시장 : 분석, 점유율, 규모, 동향, 예측(2020-2026년) Gout Therapeutics Market, By Disease Condition, By Drug Class, and By Geography - Analysis, Share, Size, Trends, & Segment Forecast from 2020-2026
발행일 : 2020년 05월 페이지 정보 : 영문 206 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

통풍 치료제(Gout Therapeutics) 시장은 2019년에 35억 6000만 달러에 달했으며, 2020-2026년의 예측 기간 중 CAGR로 16.3%의 성장이 예측됩니다.

세계의 통풍 치료제 시장에 대해 조사분석했으며, 시장 개요, 시장 역학, 부문별 시장 분석, 경쟁 구도 등에 관한 정보를 정리하여 전해드립니다.

목차

제1장 통풍 치료제 시장의 개요

  • 조사 범위
  • 전제조건과 조사 방법

제2장 개요

제3장 통풍 치료제의 주요 시장 동향

  • 시장 촉진요인
  • 시장 억제요인
  • 시장 기회
  • 시장의 미래 동향

제4장 통풍 치료제 업계 분석

  • Porter의 산업 분석
  • 마케팅 전략 분석
  • 성장 전망 지도제작
  • 규제 프레임워크 분석
  • COVID-19의 영향 분석

제5장 통풍 치료제 시장 구도

  • 시장 점유율 분석
  • 주요 이노베이터
  • 내역 데이터 : 주요 제조업체별

제6장 통풍 치료제 시장 : 약제 분류별

  • 개요
  • 코르티코스테로이드
  • NSAID
  • 요산 강하제
  • 콜히친

제7장 통풍 치료제 시장 : 병상별

  • 개요
  • 만성
  • 급성

제8장 통풍 치료제 시장 : 유통 채널별

  • 개요
  • 소매 약국
  • 병원 약국
  • 온라인 약국

제9장 통풍 치료제 시장 : 지역별

  • 서론
  • 북미
  • 유럽
  • 아시아태평양
  • 라틴아메리카
  • 중동·아프리카

제10장 주요 벤더 분석

제11장 애널리스트의 견해

제12장 부록

KSA 20.06.09

List of Tables

  • TABLE List of data sources
  • TABLE Market drivers; Impact Analysis
  • TABLE Market restraints; Impact Analysis
  • TABLE Gout Therapeutics market: Drug Class Snapshot (2018)
  • TABLE Segment Dashboard; Definition and Scope, by Drug Class
  • TABLE Global Gout Therapeutics market, by Drug Class 2015-2026 (USD Million)
  • TABLE Gout Therapeutics market: Disease Condition Snapshot (2018)
  • TABLE Segment Dashboard; Definition and Scope, by Disease Condition
  • TABLE Global Gout Therapeutics market, by Disease Condition 2015-2026 (USD Million)
  • TABLE Gout Therapeutics market: Distribution Channel Snapshot (2018)
  • TABLE Segment Dashboard; Definition and Scope, by Distribution Channel
  • TABLE Global Gout Therapeutics market, by Distribution Channel 2015-2026 (USD Million)
  • TABLE Gout Therapeutics market: Regional snapshot (2018)
  • TABLE Segment Dashboard; Definition and Scope, by Region
  • TABLE Global Gout Therapeutics market, by Region 2015-2026 (USD Million)
  • TABLE North America Gout Therapeutics market, by Country, 2015-2026 (USD Million)
  • TABLE North America Gout Therapeutics market, by Drug Class, 2015-2026 (USD Million)
  • TABLE North America Gout Therapeutics market, by Distribution Channel, 2015-2026 (USD Million)
  • TABLE North America Gout Therapeutics market, by Disease Condition, 2015-2026 (USD Million)
  • TABLE Europe Gout Therapeutics market, by country, 2015-2026 (USD Million)
  • TABLE Europe Gout Therapeutics market, by Drug Class, 2015-2026 (USD Million)
  • TABLE Europe Gout Therapeutics market, by Disease Condition, 2015-2026 (USD Million)
  • TABLE Europe Gout Therapeutics market, by Distribution Channel, 2015-2026 (USD Million)
  • TABLE Asia Pacific Gout Therapeutics market, by country, 2015-2026 (USD Million)
  • TABLE Asia Pacific Gout Therapeutics market, by Drug Class, 2015-2026 (USD Million)
  • TABLE Asia Pacific Gout Therapeutics market, by Distribution Channel, 2015-2026 (USD Million)
  • TABLE Asia Pacific Gout Therapeutics market, by Disease Condition, 2015-2026 (USD Million)
  • TABLE Latin America Gout Therapeutics market, by country, 2015-2026 (USD Million)
  • TABLE Latin America Gout Therapeutics market, by Drug Class, 2015-2026 (USD Million)
  • TABLE Latin America Gout Therapeutics market, by Distribution Channel, 2015-2026 (USD Million)
  • TABLE Latin America Gout Therapeutics market, by Disease Condition, 2015-2026 (USD Million)
  • TABLE Middle East and Africa Gout Therapeutics market, by country, 2015-2026 (USD Million)
  • TABLE Middle East and Africa Gout Therapeutics market, by Distribution Channel, 2015-2026 (USD Million)
  • TABLE Middle East and Africa Gout Therapeutics market, by Drug Class, 2015-2026 (USD Million)
  • TABLE Middle East and Africa Gout Therapeutics market, by Disease Condition, 2015-2026 (USD Million)

List of Figures

  • FIGURE Gout Therapeutics market segmentation
  • FIGURE Market research methodology
  • FIGURE Value chain analysis
  • FIGURE Porter's Five Forces Analysis
  • FIGURE Market Attractiveness Analysis
  • FIGURE COVID-19 Impact Analysis
  • FIGURE Pre & Post COVID-19 Impact Comparision Study
  • FIGURE Competitive Landscape; Key company market share analysis, 2018
  • FIGURE Drug Class segment market share analysis, 2019 & 2026
  • FIGURE Drug Class segment market size forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Corticosteroids market size forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE NSAIDS market size forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Urate-Lowering Agents market size forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Colchicine market size forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Disease Condition segment market share analysis, 2019 & 2026
  • FIGURE Disease Condition segment market size forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Chronic Gout market size forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Acute Gout market size forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Distribution Channel segment market share analysis, 2019 & 2026
  • FIGURE Distribution Channel segment market size forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Hospital Pharmacy market size forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Retail Pharmacy market size forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Online Pharmacy market size forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Regional segment market share analysis, 2019 & 2026
  • FIGURE Regional segment market size forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE North America Gout Therapeutics market share and leading players, 2018
  • FIGURE Europe Gout Therapeutics market share and leading players, 2018
  • FIGURE Asia Pacific Gout Therapeutics market share and leading players, 2018
  • FIGURE Latin America Gout Therapeutics market share and leading players, 2018
  • FIGURE Middle East and Africa Gout Therapeutics market share and leading players, 2018
  • FIGURE North America market share analysis by country, 2018
  • FIGURE U.S. Gout Therapeutics market size, forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Canada Gout Therapeutics market size, forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Europe Gout Therapeutics market share analysis by country, 2018
  • FIGURE Germany Gout Therapeutics market size, forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Spain Gout Therapeutics market size, forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Italy Gout Therapeutics market size, forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE UK Gout Therapeutics market size, forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE France Gout Therapeutics market size, forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Rest of the Europe Gout Therapeutics market size, forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Asia Pacific Gout Therapeutics market share analysis by country, 2018
  • FIGURE India Gout Therapeutics market size, forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE China Gout Therapeutics market size, forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Japan Gout Therapeutics market size, forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE South Korea Gout Therapeutics market size, forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Singapore Gout Therapeutics market size, forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Rest of APAC Gout Therapeutics market size, forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Latin America Gout Therapeutics market size, forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Latin America Gout Therapeutics market share analysis by country, 2018
  • FIGURE Brazil Gout Therapeutics market size, forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Mexico Gout Therapeutics market size, forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Argentina Gout Therapeutics market size, forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Rest of LATAM Gout Therapeutics market size, forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Middle East and Africa Gout Therapeutics market size, forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Middle East and Africa Gout Therapeutics market share analysis by country, 2018
  • FIGURE Saudi Arabia Gout Therapeutics market size, forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE United Arab Emirates Gout Therapeutics market size, forecast and trend analysis, 2015 to 2026 (USD Million)

REPORT HIGHLIGHT

Gout therapeutics market was valued at USD 3.56 billion by 2019, growing with 16.3% CAGR during the forecast period, 2020-2026

Gout is a type of disease caused by the regular occurrence of acute inflammatory arthritis, mainly when uric acid is formed in the joints. If the levels of uric acid elevate in the blood, a thin rod-like crystal can form and settle in the joints that can lead to swelling, severe pain, stiffness, tenderness, and joint damage. Gout has both active as well as inactive periods. The active periods of gout can vary in length and severity and are commonly are known as 'attacks.' Some amount of uric acid is produced by the human body when it is broken-down into purines. The diagnosis of gout is established by joint fluid analysis.

Market Dynamics

The growing adoption of regenerative drugs & biologics and introduction of numerous drugs are the major factors boosting the growth of the global gout therapeutics market. According to Center of Disease Control and Prevention (CDC), around 8.3 million adults in the U.S. alone are affected by gout every year. Furthermore, biologics such as Rilonacept, Canakinumab, and Krystexxa have been introduced in the market. These biologics have an ability to produce powerful anti-inflammatory action and thus are high in demand. In addition, various other drugs that are currently in clinical trials are projected to be launched during the period of forecast and are likely to impel the global market. For instance, the U.S. based drug discovery company, Arthrosi Therapeutics, is evaluating efficacy of AR882 drug molecule in combination with allopurinol febuxostat for the treatment of gout condition. As of, May 2020, this interventional study is undergoing Phase II clinical investigation and is projected to complete by June 2020.

Moreover, the growing prevalence of gout all over the globe owing to changing lifestyle and unhealthy habits such as heavy alcohol consumption & smoking tobacco is anticipated to create growth opportunities in the overall market. However, stringent regulations of several drugs and patent expiry are the major threats for the industry growth in the coming future. Further, the report takes into account the impact of the novel COVID-19 pandemic on the gout therapeutics market and offers a clear assessment of the projected market fluctuations during the forecast period.

Drug Class Takeaway

Based on the drug class, the worldwide gout therapeutics market is categorized into corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs), urate-lowering agents, and colchicine. Of these, the NSAIDs segment subjugated the global market in 2019 and is expected to lead the market during the forecast period. This dominance is majorly attributed to its ability to relieve pain during an acute gout attack, availability at a lower cost than other drug classes, and higher-level penetration.

On the other hand, the urate-lowering drug class segment is projected to witness the fastest growth in the estimated forecast as they majorly consist of uricosuric agents and xanthine oxidase inhibitors. In addition, the introduction of various novel drugs and increasing adoption of this treatment are likely to boost the global gout therapeutics market in the coming years.

Disease Condition Takeaway

On the basis of the disease condition, the global industry is categorized into chronic and acute gout. Among these, the chronic gout segment held the largest market share in 2019 and is estimated to dominate the market during the forecast period. This is majorly due to projected entry of pipeline drugs and introduction of urate-lowering drugs. On the other hand, the corticosteroids, NSAIDs, and colchicine are majorly utilized to treat acute gout. Thus, the acute gout segment is anticipated to grow at an impressive rate during the period of forecast. This growth is mainly owing to low treatment adherence, low-cost than urate-lowering agents, and higher penetration of drugs.

Regional Takeaway

Depending on the region, the overall industry is divided into North America, Latin America, Europe, Middle East & Africa, and the Asia Pacific. The North America region accounted for the majority of share in the gout therapeutics market in 2019 and will hold a leading position in the estimated period. This is mainly due to the presence of major industry players, high costs associated with branded pharmaceuticals, and broad use of gout therapy in this region.

On the other hand, the Asia Pacific market for gout therapeutics is expected to witness the fastest growth in the coming future owing to increasing patient pool, growing adoption of gout therapy, and increased investment by key players in this region. Furthermore, stressed lifestyle and an increase in alcohol consumption, as well as smoking prevalence, are predicted to propel the regional market growth during the forecast period.

Key Vendor Takeaway

Some of the major players operating in the global gout therapeutics market include GlaxoSmithKline, Takeda Pharmaceutical Company Ltd., Savient Pharmaceuticals, Novartis AG, Merck & Co. Inc., AstraZeneca, Teijin Pharma Limited, and Regeneron Pharmaceuticals. These companies are actively adopting various strategies such as acquisitions, collaborations, and the development of novel & innovative products to hold a strong market position.

For instance, in September 2019, JW Pharmaceutical and Simcere Pharmaceutical Group got in into a collaboration and private license agreement in China for anti-gout drug candidate URC-102. Such activities are serving the companies to enhance their presence and thereby, drive the growth all over the globe.

The market size and forecast for each segment and sub-segments has been considered as below:

Historical Year - 2015 to 2018

Base Year - 2019

Estimated Year - 2020

Projected Year - 2026

TARGET AUDIENCE

Traders, Distributors, and Suppliers

Manufacturers

Government and Regional Agencies

Research Organizations

Consultants

Distributors

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

KEY PLAYERS

GlaxoSmithKline plc

Takeda Pharmaceutical Company Ltd.

Savient Pharmaceuticals

Novartis AG

Merck & Co. Inc.

Selecta Biosciences, Inc.,

Grunenthal Group

AstraZeneca plc

Horizon Pharma Plc

Ironwood Pharmaceuticals

JW Pharmaceutical

Regeneron Pharmaceuticals

Teijin Pharma Ltd.

GOUT THERAPEUTICS MARKET, BY DRUG CLASS

Corticosteroids

NSAIDs

Urate-Lowering Agents

Colchicine

GOUT THERAPEUTICS MARKET, BY DISEASE CONDITION

Chronic Gout

Acute Gout

GOUT THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL

Retail Pharmacy

Hospital Pharmacy

Online Pharmacy

GOUT THERAPEUTICS MARKET, BY REGION

North America

U.S.

Canada

Europe

Germany

France

Italy

Spain

United Kingdom

Rest of Europe

Asia Pacific

India

China

South Korea

Japan

Singapore

Rest of APAC

Latin America

Brazil

Mexico

Argentina

Rest of LATAM

Middle East and Africa

Saudi Arabia

United Arab Emirates

Rest of MEA

TABLE OF CONTENT

1. GOUT THERAPEUTICS MARKET OVERVIEW

  • 1.1. Study Scope
  • 1.2. Assumption and Methodology

2. EXECUTIVE SUMMARY

  • 2.1. Market Snippet
    • 2.1.1. Market Snippet by Drug Class
    • 2.1.2. Market Snippet by Disease Condition
    • 2.1.3. Market Snippet by Distribution Channel
    • 2.1.4. Market Snippet by Region
  • 2.2. Competitive Insights

3. GOUT THERAPEUTICS KEY MARKET TRENDS

  • 3.1. Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Future Trends

4. GOUT THERAPEUTICS INDUSTRY STUDY

  • 4.1. Porter's Five Forces Analysis
  • 4.2. Marketing Strategy Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis
  • 4.5. COVID-19 Impact Analysis
    • 4.5.1. Pre-COVID-19 Impact Analysis
    • 4.5.2. Post-COVID-19 Impact Analysis

5. GOUT THERAPEUTICS MARKET LANDSCAPE

  • 5.1. Market Share Analysis
  • 5.2. Key Innovators
  • 5.3. Breakdown Data, by Key manufacturer
    • 5.3.1. Established Player Analysis
    • 5.3.2. Emerging Player Analysis

6. GOUT THERAPEUTICS MARKET - BY DRUG CLASS

  • 6.1. Overview
    • 6.1.1. Segment Share Analysis, By Drug Class, 2019 & 2026 (%)
  • 6.2. Corticosteroids
    • 6.2.1. Overview
    • 6.2.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
  • 6.3. NSAIDS
    • 6.3.1. Overview
    • 6.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
  • 6.4. Urate-Lowering Agents
    • 6.4.1. Overview
    • 6.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
  • 6.5. Colchicine
    • 6.5.1. Overview
    • 6.5.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)

7. GOUT THERAPEUTICS MARKET - BY DISEASE CONDITION

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Disease Condition, 2019 & 2026 (%)
  • 7.2. Chronic Gout
    • 7.2.1. Overview
    • 7.2.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
  • 7.3. Acute Gout
    • 7.3.1. Overview
    • 7.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)

8. GOUT THERAPEUTICS MARKET - BY DISTRIBUTION CHANNEL

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Distribution Channel, 2019 & 2026 (%)
  • 8.2. Retail Pharmacy
    • 8.2.1. Overview
    • 8.2.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
  • 8.3. Hospital Pharmacy
    • 8.3.1. Overview
    • 8.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
  • 8.4. Online Pharmacy
    • 8.4.1. Overview
    • 8.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)

9. GOUT THERAPEUTICS MARKET- BY GEOGRAPHY

  • 9.1. Introduction
    • 9.1.1. Segment Share Analysis, By Region, 2019 & 2026 (%)
  • 9.2. North America
    • 9.2.1. Overview
    • 9.2.2. Key Manufacturers in North America
    • 9.2.3. North America Market Size and Forecast, By Country, 2015 - 2026 (US$ Million)
    • 9.2.4. North America Market Size and Forecast, By Drug Class, 2015 - 2026 (US$ Million)
    • 9.2.5. North America Market Size and Forecast, By Distribution Channel, 2015 - 2026 (US$ Million)
    • 9.2.6. North America Market Size and Forecast, By Disease Condition, 2015 - 2026 (US$ Million)
    • 9.2.7. U.S.
      • 9.2.7.1. Overview
      • 9.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
    • 9.2.8. Canada
      • 9.2.8.1. Overview
      • 9.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
  • 9.3. Europe
    • 9.3.1. Overview
    • 9.3.2. Key Manufacturers in Europe
    • 9.3.3. Europe Market Size and Forecast, By Country, 2015 - 2026 (US$ Million)
    • 9.3.4. Europe Market Size and Forecast, By Drug Class, 2015 - 2026 (US$ Million)
    • 9.3.5. Europe Market Size and Forecast, By Distribution Channel, 2015 - 2026 (US$ Million)
    • 9.3.6. Europe Market Size and Forecast, By Disease Condition, 2015 - 2026 (US$ Million)
    • 9.3.7. Germany
      • 9.3.7.1. Overview
      • 9.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
    • 9.3.8. Italy
      • 9.3.8.1. Overview
      • 9.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
    • 9.3.9. United Kingdom
      • 9.3.9.1. Overview
      • 9.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
    • 9.3.10. France
      • 9.3.10.1. Overview
      • 9.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
    • 9.3.11. Rest of Europe
      • 9.3.11.1. Overview
      • 9.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
  • 9.4. Asia Pacific (APAC)
    • 9.4.1. Overview
    • 9.4.2. Key Manufacturers in Asia Pacific
    • 9.4.3. Asia Pacific Market Size and Forecast, By Country, 2015 - 2026 (US$ Million)
    • 9.4.4. Asia Pacific Market Size and Forecast, By Drug Class, 2015 - 2026 (US$ Million)
    • 9.4.5. Asia Pacific Market Size and Forecast, By Distribution Channel, 2015 - 2026 (US$ Million)
    • 9.4.6. Asia Pacific Market Size and Forecast, By Disease Condition, 2015 - 2026 (US$ Million)
    • 9.4.7. India
      • 9.4.7.1. Overview
      • 9.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
    • 9.4.8. China
      • 9.4.8.1. Overview
      • 9.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
    • 9.4.9. Japan
      • 9.4.9.1. Overview
      • 9.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
    • 9.4.10. South Korea
      • 9.4.10.1. Overview
      • 9.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
    • 9.4.11. Rest of APAC
      • 9.4.11.1. Overview
      • 9.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
  • 9.5. Latin America
    • 9.5.1. Overview
    • 9.5.2. Key Manufacturers in Latin America
    • 9.5.3. Latin America Market Size and Forecast, By Country, 2015 - 2026 (US$ Million)
    • 9.5.4. Latin America Market Size and Forecast, By Drug Class, 2015 - 2026 (US$ Million)
    • 9.5.5. Latin America Market Size and Forecast, By Distribution Channel, 2015 - 2026 (US$ Million)
    • 9.5.6. Latin America Market Size and Forecast, By Disease Condition, 2015 - 2026 (US$ Million)
    • 9.5.7. Brazil
      • 9.5.7.1. Overview
      • 9.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
    • 9.5.8. Mexico
      • 9.5.8.1. Overview
      • 9.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
    • 9.5.9. Argentina
      • 9.5.9.1. Overview
      • 9.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
    • 9.5.10. Rest of LATAM
      • 9.5.10.1. Overview
      • 9.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
  • 9.6. Middle East and Africa
    • 9.6.1. Overview
    • 9.6.2. Key Manufacturers in Middle East and Africa
    • 9.6.3. Middle East and Africa Market Size and Forecast, By Country, 2015 - 2026 (US$ Million)
    • 9.6.4. Middle East and Africa Market Size and Forecast, By Drug Class, 2015 - 2026 (US$ Million)
    • 9.6.5. Middle East and Africa Market Size and Forecast, By Disease Condition, 2015 - 2026 (US$ Million)
    • 9.6.6. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2015 - 2026 (US$ Million)
    • 9.6.7. Saudi Arabia
      • 9.6.7.1. Overview
      • 9.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
    • 9.6.8. United Arab Emirates
      • 9.6.8.1. Overview
      • 9.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)

10. KEY VENDOR ANALYSIS

  • 10.1. GlaxoSmithKline plc
    • 10.1.1. Company Snapshot
    • 10.1.2. Financial Performance
    • 10.1.3. Product Benchmarking
    • 10.1.4. Strategic Initiatives
  • 10.2. Takeda Pharmaceutical Company Ltd.
  • 10.3. Savient Pharmaceuticals
  • 10.4. Novartis AG
  • 10.5. Merck & Co. Inc.
  • 10.6. Selecta Biosciences, Inc.,
  • 10.7. Grunenthal Group
  • 10.8. AstraZeneca plc
  • 10.9. Horizon Pharma Plc
  • 10.10. Ironwood Pharmaceuticals
  • 10.11. JW Pharmaceutical
  • 10.12. Regeneron Pharmaceuticals
  • 10.13. Teijin Pharma Ltd.

11. 360 DEGREE ANALYSTVIEW

12. APPENDIX

  • 12.1. Research Methodology
  • 12.2. References
  • 12.3. Abbreviations
  • 12.4. Disclaimer
  • 12.5. Contact Us
Back to Top
전화 문의
F A Q